Sangamo Therapeutics Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sangamo Therapeutics (SGMO) Misses Q1 EPS by 16c, Revenues Miss
May 8, 2019 4:03 PM EDTSangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.41), $0.16 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $8 million versus the consensus estimate of $22.82 million.
"With recent encouraging clinical data in hemophilia A gene therapy and ex vivo gene-edited... More
